Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Gains from Sales and Divestitures (2022 - 2025)

Treace Medical Concepts (TMCI) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $356.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 99.9% year-over-year to $356.0, compared with a TTM value of $356.0 through Dec 2025, down 99.9%, and an annual FY2025 reading of $356.0, down 99.9% over the prior year.
  • Gains from Sales and Divestitures was $356.0 for Q4 2025 at Treace Medical Concepts, down from $342012.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $342012.0 in Q4 2024 and bottomed at $356.0 in Q4 2025.
  • Average Gains from Sales and Divestitures over 4 years is $124627.5, with a median of $78071.0 recorded in 2022.
  • The sharpest move saw Gains from Sales and Divestitures skyrocketed 2309.11% in 2023, then tumbled 99.9% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $6223.0 in 2022, then surged by 2309.11% to $149919.0 in 2023, then surged by 128.13% to $342012.0 in 2024, then crashed by 99.9% to $356.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for TMCI at $356.0 in Q4 2025, $342012.0 in Q4 2024, and $149919.0 in Q4 2023.